ConductScience.org, home

Paper40485603

Mechanistic Foundations of KRAS-Driven Tumor Ecosystems: Integrating Crosstalk among Immune, Metabolic, Microbial, and Stromal Microenvironment.

Ma J and 9 others. Adv Sci (Weinh), 2025. Cited by 16 papers, by iCite.

Cite this record

ConductScience Library. Mechanistic Foundations of KRAS-Driven Tumor Ecosystems: Integrating Crosstalk among Immune, Metabolic, Microbial, and Stromal Microenvironment. Papers, record 40485603. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40485603

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Mechanistic Foundations of KRAS-Driven Tumor Ecosystems: Integrating Crosstalk among Immune, Metabolic, Microbial, and Stromal Microenvironment.
PubMed
Journal
Adv Sci (Weinh)
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
16
iCite
Relative citation ratio, by iCite
3.54, provisional
iCite
Revised in PubMed
2025-08-27
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ma JJiayao
2Fu SShenao
3Tan JJun
4Han YYing
5Chen YYihong
6Deng XXiangying
7Shen HHong
8Zeng SShanhttps://orcid.org/0000-0002-0988-723X
9Peng YYinghui
10Cai CChangjing

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Tumor MicroenvironmentMajor topic
Proto-Oncogene Proteins p21(ras)Major topic
NeoplasmsMajor topic
Humans
Animals
Mutation
Microbiota

Source PubMed

Download CSV of topics

Grants11

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
82173342National Natural Science Foundation of ChinaPubMed
82203015National Natural Science Foundation of ChinaPubMed
82373275National Natural Science Foundation of ChinaPubMed
82403920National Natural Science Foundation of ChinaPubMed
2024JJ6662Natural Science Foundation of Hunan ProvincePubMed
2025JJ20077Natural Science Foundation of Hunan ProvincePubMed
2024RC3042Science and Technology Innovation Program of Hunan ProvincePubMed
2023Q01Youth Science Foundation of Xiangya HospitalPubMed
GZC20242044Postdoctoral Fellowship Program of the CPSFPubMed
2024M753679China Postdoctoral Science FoundationPubMed
kq2403008Nature Science Foundation of ChangshaPubMed

Source PubMed

Download CSV of grants

References158

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126037647Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.Mol Cancer Res2015https://conductscience.org/library/papers/26037647PubMed
223852309
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.
Ann Oncol2013https://conductscience.org/library/papers/23852309PubMed
332467386The human tumor microbiome is composed of tumor type-specific intracellular bacteria.Science2020https://conductscience.org/library/papers/32467386PubMed
435219699Mucin 5AC-Mediated CD44/ITGB1 Clustering Mobilizes Adipose-Derived Mesenchymal Stem Cells to Modulate Pancreatic Cancer Stromal Heterogeneity.Gastroenterology2022https://conductscience.org/library/papers/35219699PubMed
534644529Spatially confined sub-tumor microenvironments in pancreatic cancer.Cell2021https://conductscience.org/library/papers/34644529PubMed
635836817Integrated multi-omics characterization of KRAS mutant colorectal cancer.Theranostics2022https://conductscience.org/library/papers/35836817PubMed
731578522The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL.Nature2019https://conductscience.org/library/papers/31578522PubMed
834244683Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment.Nat Rev Cancer2021https://conductscience.org/library/papers/34244683PubMed
921646616Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.J Clin Oncol2011https://conductscience.org/library/papers/21646616PubMed
1031827278Plasma membrane V-ATPase controls oncogenic RAS-induced macropinocytosis.Nature2019https://conductscience.org/library/papers/31827278PubMed
1133870211The Metabolic Landscape of RAS-Driven Cancers from biology to therapy.Nat Cancer2021https://conductscience.org/library/papers/33870211PubMed
1230721664Early Detection of Pancreatic Cancer: Opportunities and Challenges.Gastroenterology2019https://conductscience.org/library/papers/30721664PubMed
1332814111In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.Gastroenterology2020https://conductscience.org/library/papers/32814111PubMed
1438402201Fusobacterium nucleatum promotes tumor progression in KRAS p.G12D-mutant colorectal cancer by binding to DHX15.Nat Commun2024https://conductscience.org/library/papers/38402201PubMed
1531827279KRAS4A directly regulates hexokinase 1.Nature2019https://conductscience.org/library/papers/31827279PubMed
1630738221Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).J Thorac Oncol2019https://conductscience.org/library/papers/30738221PubMed
1736229606Metabolic communication in the tumour-immune microenvironment.Nat Cell Biol2022https://conductscience.org/library/papers/36229606PubMed
1837344586Injury prevents Ras mutant cell expansion in mosaic skin.Nature2023https://conductscience.org/library/papers/37344586PubMed
1924464042Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation.Nat Neurosci2014https://conductscience.org/library/papers/24464042PubMed
2037775182Stromal-derived NRG1 enables oncogenic KRAS bypass in pancreas cancer.Genes Dev2023https://conductscience.org/library/papers/37775182PubMed

See all 158 referencesDownload CSV of references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.

PMIDTitleJournalYearIn PapersSource
42817222Mapping Mutations and Signaling Network Interactions to Guide Precision Therapy in Gallbladder Cancer.Cancer Rep (Hoboken)2026https://conductscience.org/library/papers/42817222PubMed
42729994Bracing for the storm: emerging resistance mechanisms to KRAS inhibitors in pancreatic cancer and strategies to overcome them.Cancer Drug Resist2026https://conductscience.org/library/papers/42729994PubMed
42490421KRASG12D inhibition reprograms the tumor-induced immunosuppressive environment and enhances NK cell-mediated antitumor immunity.Sci Adv2026https://conductscience.org/library/papers/42490421PubMed
42465857Microbiota in pancreatic cancer: Roles in tumor initiation and progression (Review).Oncol Lett2026https://conductscience.org/library/papers/42465857PubMed
42218726Current advances in immunotherapy for KRAS-Mutant pancreatic cancer.Clin Exp Med2026https://conductscience.org/library/papers/42218726PubMed
42164352DARS2 serves as an independent prognostic factor and participates in multiple biological processes in bladder urothelial carcinoma.Transl Androl Urol2026https://conductscience.org/library/papers/42164352PubMed
42122957Pancreatic Cancer in the Holobiont and Therapeutic Targets: A Review.J Clin Med2026https://conductscience.org/library/papers/42122957PubMed
41924551Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.Drug Des Devel Ther2026https://conductscience.org/library/papers/41924551PubMed
41836721From Barrier to Gateway: Nanomaterials Reshaping the Tumor Microenvironment for Therapy.Int J Nanomedicine2026https://conductscience.org/library/papers/41836721PubMed
41827015Systematic and precise interventions for KRAS-mutant cancers.Exp Hematol Oncol2026https://conductscience.org/library/papers/41827015PubMed
40936169Novel Evolutionarily Conserved Oncogene COA4 is Driven by KRAS Mutant and Promotes Cancer Metastasis Through Dual Mitochondrial Metabolism-Dependent and -Independent Mechanisms.Adv Sci (Weinh)2025https://conductscience.org/library/papers/40936169PubMed
40725204RETRACTED: The Impact of Fusobacterium nucleatum and the Genotypic Biomarker KRAS on Colorectal Cancer Pathogenesis.Int J Mol Sci2025https://conductscience.org/library/papers/40725204PubMed
40485603Mechanistic Foundations of KRAS-Driven Tumor Ecosystems: Integrating Crosstalk among Immune, Metabolic, Microbial, and Stromal Microenvironment.Adv Sci (Weinh)2025https://conductscience.org/library/papers/40485603PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40485603

GET https://conductscience.org/api/papers/v1/40485603/references?page=2